Neurotoxic in vivo models of Parkinson's disease: recent advances

被引:140
作者
Bjorklund, Anders [1 ]
Cenci, M. Angela [2 ]
机构
[1] Lund Univ, Div Neurobiol, Wallenberg Neurosci Ctr, Lund, Sweden
[2] Lund Univ, Dept Expt Med Sci, Basal Ganglia Pathophysiol Unit, Lund, Sweden
来源
RECENT ADVANCES IN PARKINSONS DISEASE: TRANSLATIONAL AND CLINICAL RESEARCH | 2010年 / 184卷
关键词
Parkinson's disease; neurotoxin; animal models; ENVIRONMENTAL RISK-FACTORS; HUMAN ALPHA-SYNUCLEIN; NIGRAL DOPAMINERGIC-NEURONS; DJ-1-DEFICIENT MICE; DEFICIENT MICE; L-DOPA; OXIDATION MECHANISMS; INDUCED DEGENERATION; STRIATAL DOPAMINE; COENZYME Q(10);
D O I
10.1016/S0079-6123(10)84002-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Animal models have been invaluable to Parkinson's disease (PD) research. Of these, neurotoxin models have historically been the most widely utilized. The goal of this chapter is to give a brief historical description of classic PD models and then to identify the most recent important advances in modeling human PD in animals. Indeed, significant advances in modeling additional features of PD and expansion to new species have occurred in both older and newer models. The roles these new advances in modeling may have in future PD research are examined in this chapter.
引用
收藏
页码:17 / 33
页数:17
相关论文
共 155 条
[1]   Range of neuropsychiatric disturbances in patients with Parkinson's disease [J].
Aarsland, D ;
Larsen, JP ;
Lim, NG ;
Janvin, C ;
Karlsen, K ;
Tandberg, E ;
Cummings, JL .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (04) :492-496
[2]   L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats [J].
Alam, M ;
Schmidt, WJ .
BEHAVIOURAL BRAIN RESEARCH, 2004, 153 (02) :439-446
[3]   Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats [J].
Alam, M ;
Schmidt, WJ .
BEHAVIOURAL BRAIN RESEARCH, 2002, 136 (01) :317-324
[4]   Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease [J].
Anderson, Grant ;
Noorian, All Reza ;
Taylor, Georgia ;
Anitha, Mallappa ;
Bernhard, Doug ;
Srinivasan, Shanthi ;
Greene, James G. .
EXPERIMENTAL NEUROLOGY, 2007, 207 (01) :4-12
[5]   THE DETERMINATION OF HYDROXYDOPAMINES AND OTHER TRACE AMINES IN THE URINE OF PARKINSONIAN-PATIENTS AND NORMAL CONTROLS [J].
ANDREW, R ;
WATSON, DG ;
BEST, SA ;
MIDGLEY, JM ;
WENLONG, H ;
PETTY, RKH .
NEUROCHEMICAL RESEARCH, 1993, 18 (11) :1175-1177
[6]   TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates [J].
Andringa, G ;
Eshuis, S ;
Perentes, E ;
Maguire, RP ;
Roth, D ;
Ibrahim, M ;
Leenders, KL ;
Cools, AR .
NEUROBIOLOGY OF DISEASE, 2003, 14 (02) :205-217
[7]  
[Anonymous], 1919, CONTRIBUTION ETUDE A
[8]   Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone [J].
Antkiewicz-Michaluk, L ;
Wardas, J ;
Michaluk, J ;
Romanska, I ;
Bojarski, A ;
Vetulani, J .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (02) :155-163
[9]   Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice [J].
Asanuma, M ;
Hirata, H ;
Cadet, JL .
NEUROSCIENCE, 1998, 85 (03) :907-917
[10]   COMPARATIVE BEHAVIORAL, BIOCHEMICAL AND PIGMENTARY EFFECTS OF MPTP, MPP+ AND PARAQUAT IN RANA-PIPIENS [J].
BARBEAU, A ;
DALLAIRE, L ;
BUU, NT ;
POIRIER, J ;
RUCINSKA, E .
LIFE SCIENCES, 1985, 37 (16) :1529-1538